Table 1.
Demographic and clinical characteristics of the whole sample and PTSD subgroups.
| Variable | Total | PTSD symptoms | P-value | |
|---|---|---|---|---|
| (N = 574) | Yes (N = 64) | No (N = 510) | ||
| N (%) | N (%) | N (%) | ||
| Sex | ||||
| Male | 226 (39.4) | 16 (25.0) | 210 (41.2) | 0.013 |
| Female | 348 (60.6) | 48 (75.0) | 300 (58.8) | |
| Severe COVID-19 infection | 113 (19.7) | 16 (25.0) | 97 (19.0) | 0.257 |
| Comorbidity | ||||
| Total | 245 (42.7) | 26 (40.6) | 219 (42.9) | 0.637 |
| Hypertension | 156 (27.2) | 16 (25.0) | 140 (27.5) | 0.678 |
| Diabetes | 84 (14.6) | 6 (9.4) | 78 (15.3) | 0.207 |
| Coronary heart disease | 37 (6.4) | 4 (6.3) | 33 (6.5) | 1.000a |
| Chronic lung disease | 22 (3.8) | 4 (6.3) | 18 (3.5) | 0.130a |
| Chronic kidney disease | 7 (1.2) | 0 | 7 (1.4) | 1.000a |
| Chronic liver disease | 12 (2.1) | 2 (3.1) | 10 (2.0) | 0.633a |
| Cerebrovascular disease | 13 (2.3) | 3 (4.7) | 10 (2.0) | 0.168a |
| Cancer | 16 (2.8) | 0 | 16 (2.8) | 0.238a |
| Clinical sequelae at discharge | 381 (66.4) | 54 (84.4) | 327 (64.1) | 0.001 |
| Clinical sequelae at follow-up | 447 (77.9) | 64 (100.0) | 383 (75.1) | <0.001 |
| Mean (SD) | Mean (SD) | Mean (SD) | P -value | |
| Age (years) | 57.67 (11.42) | 57.25 (10.62) | 57.72 (11.53) | 0.757b |
| Time from symptom onset to admission (days) | 29.75 (16.30) | 31.90 (18.09) | 29.48 (16.06) | 0.282b |
| Length of hospital stay (days) | 18.49 (12.17) | 19.91 (12.39) | 18.31 (12.15) | 0.324b |
| Time from discharge to follow-up (days) | 193.99 (15.32) | 192.31 (13.95) | 194.21 (15.48) | 0.352b |
a
Fisher's exact test.
b
Two independent-samples T-test.
Bold values: P < 0.05.